Highlights BioArctic AB

Equities

BIOA B

SE0010323311

Market Closed - Nasdaq Stockholm Other stock markets 11:29:39 2024-05-17 am EDT			5-day change	1st Jan Change
230.2 ^SEK	-0.78%		+13.40%	-14.04%

May. 17	Transcript : BioArctic AB, Q1 2024 Earnings Call, May 17, 2024
May. 17	BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 17	CI
BioArctic, Eisai Launch Rolling US FDA Application for Leqembi's Maintenance Dosing	May. 15	MT
BioArctic AB and Eisai Co., Ltd. Sign Research Evaluation Agreement Regarding BAN2802	Apr. 20	CI
Nordic Shares Moved Upward Monday; Invisio Led Increases	Apr. 15	DJ
Nordic Stocks Rose Friday; BioArctic Series B Climbed Highest	Apr. 12	DJ
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	Apr. 01	MT
Nordic Stocks Declined Friday; BioArctic Series B Took Biggest Hit	Mar. 22	DJ
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	Mar. 22	MT
BioArctic AB and its Partner Eisai Present New Data on Lecanemab at 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders	Mar. 11	CI
BioArctic AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 14	CI
BioArctic AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 14	CI
Eisai expects 1,500 Alzheimer's patients in China launch, sees 'huge' growth	Feb. 04	RE
The European Medicines Agency's Scientific Advisory Group to Discuss the Marketing Authorisation Application for lecanemab	Jan. 11	CI
BioArctic's Partner Obtains Marketing Authorization for Leqembi in China	Jan. 09	MT
Leqembi® Approves for the Treatment of Alzheimer's Disease in China	Jan. 09	CI
BioArctic, Eisai Sets Launch Date for Alzheimer’s Disease Drug in Japan	Dec. 13	MT
BioArctic AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Injected version of Eisai/Biogen Alzheimer's drug works as well as IV Leqembi	23-10-25	RE
BioArctic AB's Presents New Data on the Investigational Subcutaneous Formulation of LEQEMBI	23-10-25	CI
Japan Approves BioArctic's Treatment to Slow Effects of Alzheimer's Disease	23-09-25	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioArctic AB

Equities

BIOA B

SE0010323311

Highlights

Filters